BRIJ Medical Welcomes Tim Gleeson as CEO and Joe Andrew as SVP of Sales

BRIJ Medical is pleased to announce the appointment of Tim Gleeson as CEO and Joe Andrew as Senior Vice President of Sales. These strategic appointments signify a significant milestone for BRIJ Medical as they usher in a new era of post-surgical and trauma incision care with proven technologies that minimize wound complications and scarring.

With over two decades of experience in executive leadership roles within the medical device sector, Tim Gleeson brings a wealth of expertise to his new role as CEO. His success founding and leading Novasyte to a strategic exit by IQVIA, along with executive roles at Medtronic, aligns seamlessly with BRIJ Medical’s commitment to advancing patient outcomes through innovative wound management technologies.

Joe Andrew

As the Senior Vice President of Sales, Joe Andrew will lead BRIJ Medical’s commercial strategies and team expansion efforts, drawing on his extensive experience in sales and business development from his tenure as founder and executive leader at Novasyte. With a focus on cultivating strategic partnerships and expanding market presence, Joe will play a pivotal role in driving revenue growth and market penetration for BRIJ Medical’s technologies.

Monte” Eaves, MD

“We are pleased to welcome Tim and Joe to our executive team,” said Felmont “Monte” Eaves, MD, Founder and Chief Medical Officer at BRIJ Medical. “Their combined expertise and leadership will be instrumental in steering BRIJ Medical towards continued success and innovation. As we embark on this new chapter, we remain committed to delivering technologies that support every stage of the healing journey, improve outcomes, and increase patient confidence.”

Tim Gleeson

Tim Gleeson expressed his excitement about joining BRIJ Medical, stating, “I am honored to lead BRIJ Medical during this exciting phase of growth and innovation. With a talented team and a portfolio of groundbreaking products, I am confident that we will achieve new heights in delivering value to healthcare providers and patients alike.”

Joe Andrew expressed his enthusiasm, stating, “I am thrilled to join BRIJ Medical and contribute to its mission of transforming patient care and outcomes. I look forward to leveraging my experience in building world class sales teams, driving wide scale clinical adoption and forging meaningful partnerships.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”